Open Access

Telmisartan inhibits bladder smooth muscle fibrosis in neurogenic bladder rats

  • Authors:
    • Qian Liu
    • Ruoyi Wang
    • Nan Ma
    • Chuntian Wang
    • Weixiu Chen
  • View Affiliations

  • Published online on: January 11, 2022     https://doi.org/10.3892/etm.2022.11140
  • Article Number: 216
  • Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Hypertension is associated with bladder symptoms. The present study investigated whether an angiotensin receptor blocker could improve the symptoms and pathological changes associated with a neurogenic bladder (NB). A Sprague‑Dawley rat model of NB was constructed. Rats in the sham and model groups were gavaged with saline, and rats in the treatment group were gavaged with telmisartan. Urodynamic parameters, including maximum cystometric capacity, residual urine volume, bladder wet weight, bladder compliance and detrusor pressure, were detected. Masson and H&E staining were performed to assess bladder fibrosis and histopathological changes. The expression levels of basic fibroblast growth factor (bFGF), TGF‑β1, Collagen I, Collagen III, and α‑smooth muscle actin (α‑SMA) were also measured by reverse transcription‑quantitative PCR, western blotting and immunohistochemistry. The model rats exhibited symptoms and pathological changes associated with NB. Treatment with telmisartan reduced maximum cystometric capacity, residual urine volume, bladder compliance and bladder wet weight, and increased detrusor pressure in model rats. The tissue staining results showed that telmisartan exerted an antifibrotic effect. In addition, telmisartan inhibited the expression of bFGF, TGF‑β1, Collagen I, Collagen III and α‑SMA in model rats. Therefore, the results of the present study indicated that telmisartan may serve as a potential therapeutic agent for NB.
View Figures
View References

Related Articles

Journal Cover

March-2022
Volume 23 Issue 3

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Liu Q, Wang R, Ma N, Wang C and Chen W: Telmisartan inhibits bladder smooth muscle fibrosis in neurogenic bladder rats. Exp Ther Med 23: 216, 2022
APA
Liu, Q., Wang, R., Ma, N., Wang, C., & Chen, W. (2022). Telmisartan inhibits bladder smooth muscle fibrosis in neurogenic bladder rats. Experimental and Therapeutic Medicine, 23, 216. https://doi.org/10.3892/etm.2022.11140
MLA
Liu, Q., Wang, R., Ma, N., Wang, C., Chen, W."Telmisartan inhibits bladder smooth muscle fibrosis in neurogenic bladder rats". Experimental and Therapeutic Medicine 23.3 (2022): 216.
Chicago
Liu, Q., Wang, R., Ma, N., Wang, C., Chen, W."Telmisartan inhibits bladder smooth muscle fibrosis in neurogenic bladder rats". Experimental and Therapeutic Medicine 23, no. 3 (2022): 216. https://doi.org/10.3892/etm.2022.11140